Yeast Surface Display Platform Could Improve Characterization of CAR-T Cell Functionality

An international team of scientists, including researchers from the Technical University of Denmark (DTU), has developed a yeast surface display platform that can accelerate and refine the study of cancer immunotherapies. By modifying yeast cells to mimic human cancer cells, the system allows faster, cheaper testing of therapies that rely on engineered immune cells. The research, published in Nature Communications, demonstrates the potential of the platform to shorten experimental evaluation of CAR T cell performance from months to days or weeks.

The platform uses common yeast cells that have been genetically engineered to display human cancer antigens on their surface. These modified yeast strains serve as biological test screens, enabling researchers to observe how patient-derived immune cells—specifically chimeric antigen receptor (CAR) T cells—interact with different cancer-related targets.

Co-author Sine Reker Hadrup from DTU Health Technology explained, “The most surprising thing for us was how accurately the engineered yeast cells could mimic real cancer cells. They activated CAR T cells almost as effectively as traditional cancer cell lines—and in some cases even more robustly.” She added that the platform’s combination of precision, speed, and low cost makes large-scale testing of new immunotherapies possible in ways that were not feasible before.

CAR T cell therapy has proved highly effective for blood cancers but remains difficult and expensive to extend to solid tumors. Even small variations in tumor antigens between individuals can determine whether the therapy succeeds or fails. The new yeast-based model seeks to make this process more systematic and predictable.

By inserting specific antigen “recipes” into yeast, scientists create cells that display these antigens on their surface as cancer cells would. When CAR T cells are exposed to them, their reactions can be measured rapidly, supporting better understanding of CAR T function. This approach provides a faster, less expensive alternative to growing human cancer cell lines or advanced nanotechnological systems.

According to the DTU team, the yeast platform grows quickly, adapts within days, and is accessible to a range of laboratories. They note that it enables systematic evaluation of multiple antigen types and may help identify improved, safer, and more targeted CAR T therapies in the future.